(Q38155201)

29 August 2017

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder (English)

1 reference

29 August 2017

1 reference

Christina Ann Ortmann

series ordinal

1

1 reference

PubMed ID

24156324

29 August 2017

Danish Mazhar

series ordinal

2

1 reference

PubMed ID

24156324

29 August 2017

language of work or name

English

0 references

publication date

1 November 2013

1 reference

29 August 2017

1 reference

29 August 2017

9

1 reference

29 August 2017

1637-1651

1 reference

29 August 2017

11

1 reference

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

29 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Update on chemotherapy for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Vinflunine: a new microtubule inhibitor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Antitumor activity of vinflunine: effector pathways and potential for synergies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Potential mechanisms of resistance to microtubule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A Phase II study of oxaliplatin in urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Bladder cancer: translating molecular genetic insights into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.139

21 January 2018

Identifiers

DOI

10.2217/FON.13.139

1 reference

29 August 2017

1 reference

PubMed ID

24156324